Alumis Inc.
↗South San Francisco, USA
Alumis is a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases. The company leverages a precision data analytics platform to identify and advance targeted therapies, with a primary focus on modulating the tyrosine kinase 2 (TYK2) pathway.
Its lead candidate, envudeucitinib, is a highly selective, allosteric TYK2 inhibitor currently in late-stage development for moderate-to-severe plaque psoriasis and systemic lupus erythematosus (SLE). The company is also developing A-005, a CNS-penetrant TYK2 inhibitor, and lonigutamab, a monoclonal antibody for thyroid eye disease.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$20M-$30M
Founded:2021
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$529M
Investors:Foresite Capital, Samsara BioCapital, venBio Partners, Cormorant Asset Management, SR One, Lilly Asia Ventures, Nextech, Ally Bridge Group, HBM Healthcare Investments, Omega Funds, Piper Heartland Healthcare
STOCK
Exchange:NASDAQ
Ticker:ALMS
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule, mAb
Active Trials:20
Trial Phases:Phase 2: 1 | Phase 3: 3
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
Competitors:Moderna, argenx, Annexon, Bristol Myers Squibb
LEADERSHIP
Key Executives:
Martin Babler - President, CEO & Chairman
Jörn Drappa - Chief Medical Officer
Board Members:Alan B. Colowick, Sapna Srivastava, C. Patrick Machado, James Bruce Tananbaum, Zhengbin Yao, Srinivas Akkaraju, Lynn A. Tetrault
LINKS
Website:alumis.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Alumis Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Alumis Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.